Novo Nordisk/LinkedIn
Oct 31, 2025, 14:21
Novo Nordisk Submits Biologics License Application for Mim8 (Denecimig) in Hemophilia A
National Bleeding Disorders Foundation (NBDF) shared on LinkedIn:
”Novo Nordisk has submitted a Biologics License Application (BLA) for Mim8 (denecimig), a promising bispecific antibody therapy for people with hemophilia A, with or without inhibitors.
Mim8 may offer more flexible dosing options and an easier treatment experience through a single-use, prefilled injector pen.
Learn more about this milestone”
Read the full announcement here.
Stay updated on the emerging with Hemostasis Today.
-
Oct 2, 2026, 18:34Kamini Khillan: Massive Transfusion Protocol for PPH Management
-
Oct 2, 2026, 18:24Garima Sharma։ GLP-1 Receptor Agonists Across the Reproductive Life Course
-
Oct 2, 2026, 18:13Priya Sriskandarajah: Roginolisib Plus JAK Inhibitors in Myelofibrosis
-
Oct 2, 2026, 17:40Chokri Ben Lamine: A Two-Day Journey Through Modern Hematology at KFSHRC
-
Oct 2, 2026, 17:27Reza Shojaei: The Invisible Crisis, Part 1- Donor Deferral in Whole Blood
-
Oct 2, 2026, 16:02Advancing Antithrombotic Stewardship to Optimise Care – American Heart Association
-
Oct 2, 2026, 15:37Pall T. Onundarson: Monitoring Warfarin Beyond Factor VII
-
Oct 2, 2026, 15:26Nicola Carter: World Thrombosis Day Highlights Gender Specific Risks and Prevention
-
Oct 2, 2026, 14:56Wolfgang Miesbach: Direct Comparison Reveals Distinct Mechanisms Among FVIIIa Mimetics